242 related articles for article (PubMed ID: 32891712)
1. Co-administration of sulforaphane and doxorubicin attenuates breast cancer growth by preventing the accumulation of myeloid-derived suppressor cells.
Rong Y; Huang L; Yi K; Chen H; Liu S; Zhang W; Yuan C; Song X; Wang F
Cancer Lett; 2020 Nov; 493():189-196. PubMed ID: 32891712
[TBL] [Abstract][Full Text] [Related]
2. Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model.
Bose C; Awasthi S; Sharma R; Beneš H; Hauer-Jensen M; Boerma M; Singh SP
PLoS One; 2018; 13(3):e0193918. PubMed ID: 29518137
[TBL] [Abstract][Full Text] [Related]
3. Sulforaphane activates CD8
Liu J; Chen H; Guo C; Li J; Li M; Zhao M; Fu Z; Zhang Z; Li F; Zhao X; Yang L; Wang L; Lv Q; Zhang Y
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38296593
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
5. Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis.
Deng Z; Rong Y; Teng Y; Zhuang X; Samykutty A; Mu J; Zhang L; Cao P; Yan J; Miller D; Zhang HG
Oncogene; 2017 Feb; 36(5):639-651. PubMed ID: 27345402
[TBL] [Abstract][Full Text] [Related]
6. A RIPK3-PGE
Yan G; Zhao H; Zhang Q; Zhou Y; Wu L; Lei J; Wang X; Zhang J; Zhang X; Zheng L; Du G; Xiao W; Tang B; Miao H; Li Y
Cancer Res; 2018 Oct; 78(19):5586-5599. PubMed ID: 30012671
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2.
Rong Y; Yuan CH; Qu Z; Zhou H; Guan Q; Yang N; Leng XH; Bu L; Wu K; Wang FB
Sci Rep; 2016 Apr; 6():23824. PubMed ID: 27032536
[TBL] [Abstract][Full Text] [Related]
8. Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid.
Li ZY; Yin YF; Guo Y; Li H; Xu MQ; Liu M; Wang JR; Feng ZH; Duan XC; Zhang S; Zhang SQ; Wang GX; Liao A; Wang SM; Zhang X
Int J Nanomedicine; 2020; 15():1809-1821. PubMed ID: 32214813
[TBL] [Abstract][Full Text] [Related]
9. TRAIL attenuates sulforaphane-mediated Nrf2 and sustains ROS generation, leading to apoptosis of TRAIL-resistant human bladder cancer cells.
Jin CY; Molagoda IMN; Karunarathne WAHM; Kang SH; Park C; Kim GY; Choi YH
Toxicol Appl Pharmacol; 2018 Aug; 352():132-141. PubMed ID: 29792947
[TBL] [Abstract][Full Text] [Related]
10. Sulforaphane protects the heart from doxorubicin-induced toxicity.
Singh P; Sharma R; McElhanon K; Allen CD; Megyesi JK; Beneš H; Singh SP
Free Radic Biol Med; 2015 Sep; 86():90-101. PubMed ID: 26025579
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with liposomal doxorubicin and liposomal vaccine containing E75, an HER-2/neu-derived peptide, reduces myeloid-derived suppressor cells and improved tumor therapy.
Zamani P; Navashenaq JG; Teymouri M; Karimi M; Mashreghi M; Jaafari MR
Life Sci; 2020 Jul; 252():117646. PubMed ID: 32272178
[TBL] [Abstract][Full Text] [Related]
12. RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells.
Soong RS; Anchoori RK; Yang B; Yang A; Tseng SH; He L; Tsai YC; Roden RB; Hung CF
Oncotarget; 2016 Oct; 7(42):68489-68502. PubMed ID: 27655678
[TBL] [Abstract][Full Text] [Related]
13. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages.
Liu Z; Xie Y; Xiong Y; Liu S; Qiu C; Zhu Z; Mao H; Yu M; Wang X
Cancer Lett; 2020 Jan; 469():173-185. PubMed ID: 31629935
[TBL] [Abstract][Full Text] [Related]
14. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin pretreatment enhances FAPα/survivin co-targeting DNA vaccine anti-tumor activity primarily through decreasing peripheral MDSCs in the 4T1 murine breast cancer model.
Geng F; Bao X; Dong L; Guo QQ; Guo J; Xie Y; Zhou Y; Yu B; Wu H; Wu JX; Zhang HH; Yu XH; Kong W
Oncoimmunology; 2020; 9(1):1747350. PubMed ID: 32363118
[TBL] [Abstract][Full Text] [Related]
16. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
17. Crucifera sulforaphane (SFN) inhibits the growth of nasopharyngeal carcinoma through DNA methyltransferase 1 (DNMT1)/Wnt inhibitory factor 1 (WIF1) axis.
Chen L; Chan LS; Lung HL; Yip TTC; Ngan RKC; Wong JWC; Lo KW; Ng WT; Lee AWM; Tsao GSW; Lung ML; Mak NK
Phytomedicine; 2019 Oct; 63():153058. PubMed ID: 31394414
[TBL] [Abstract][Full Text] [Related]
18. Sulforaphane inhibits cancer stem-like cell properties and cisplatin resistance through miR-214-mediated downregulation of c-MYC in non-small cell lung cancer.
Li QQ; Xie YK; Wu Y; Li LL; Liu Y; Miao XB; Liu QZ; Yao KT; Xiao GH
Oncotarget; 2017 Feb; 8(7):12067-12080. PubMed ID: 28076844
[TBL] [Abstract][Full Text] [Related]
19. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase.
Lin Y; Cai Q; Chen Y; Shi T; Liu W; Mao L; Deng B; Ying Z; Gao Y; Luo H; Yang X; Huang X; Shi Y; He R
Hepatology; 2022 Jan; 75(1):28-42. PubMed ID: 34387870
[TBL] [Abstract][Full Text] [Related]
20. Single Cell Mass Cytometry Revealed the Immunomodulatory Effect of Cisplatin Via Downregulation of Splenic CD44+, IL-17A+ MDSCs and Promotion of Circulating IFN-γ+ Myeloid Cells in the 4T1 Metastatic Breast Cancer Model.
Balog JÁ; Hackler L; Kovács AK; Neuperger P; Alföldi R; Nagy LI; Puskás LG; Szebeni GJ
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31881770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
